Current and future nanoparticle vaccines for COVID-19

COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mai N. Vu, Hannah G. Kelly, Stephen J. Kent, Adam K. Wheatley
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	nanoparticle vaccine COVID-19 vaccine SARS-CoV-2 neutralizing antibody protein nanoparticle Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/dadbf14de8d1459d8d7e587ed362bfa6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dadbf14de8d1459d8d7e587ed362bfa6
record_format	dspace
spelling	oai:doaj.org-article:dadbf14de8d1459d8d7e587ed362bfa62021-11-20T05:06:58ZCurrent and future nanoparticle vaccines for COVID-192352-396410.1016/j.ebiom.2021.103699https://doaj.org/article/dadbf14de8d1459d8d7e587ed362bfa62021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S235239642100493Xhttps://doaj.org/toc/2352-3964COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.Mai N. VuHannah G. KellyStephen J. KentAdam K. WheatleyElsevierarticlenanoparticle vaccineCOVID-19 vaccineSARS-CoV-2neutralizing antibodyprotein nanoparticleMedicineRMedicine (General)R5-920ENEBioMedicine, Vol 74, Iss , Pp 103699- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanoparticle vaccine COVID-19 vaccine SARS-CoV-2 neutralizing antibody protein nanoparticle Medicine R Medicine (General) R5-920
spellingShingle	nanoparticle vaccine COVID-19 vaccine SARS-CoV-2 neutralizing antibody protein nanoparticle Medicine R Medicine (General) R5-920 Mai N. Vu Hannah G. Kelly Stephen J. Kent Adam K. Wheatley Current and future nanoparticle vaccines for COVID-19
description	COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.
format	article
author	Mai N. Vu Hannah G. Kelly Stephen J. Kent Adam K. Wheatley
author_facet	Mai N. Vu Hannah G. Kelly Stephen J. Kent Adam K. Wheatley
author_sort	Mai N. Vu
title	Current and future nanoparticle vaccines for COVID-19
title_short	Current and future nanoparticle vaccines for COVID-19
title_full	Current and future nanoparticle vaccines for COVID-19
title_fullStr	Current and future nanoparticle vaccines for COVID-19
title_full_unstemmed	Current and future nanoparticle vaccines for COVID-19
title_sort	current and future nanoparticle vaccines for covid-19
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/dadbf14de8d1459d8d7e587ed362bfa6
work_keys_str_mv	AT mainvu currentandfuturenanoparticlevaccinesforcovid19 AT hannahgkelly currentandfuturenanoparticlevaccinesforcovid19 AT stephenjkent currentandfuturenanoparticlevaccinesforcovid19 AT adamkwheatley currentandfuturenanoparticlevaccinesforcovid19
_version_	1718419571835142144

Current and future nanoparticle vaccines for COVID-19

Ejemplares similares